GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified... Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.
- Mechanism
- Curator reviewed
The mechanism of action for GI-5005 (i.e. immune elimination of infected hepatic cells) may work synergistically in combination with the current or emerging standard of care, which directly inhibits viral replication, to more effectively eradicate hepatitis C virus from the liver. Additionally, this mechanism of action may offer an option for interferon-intolerant or interferon-contraindicated patients as a long term monotherapy.
GI-5005 is designed to elicit a cellular immune response against cells infected with the HCV virus. The yeast vector is designed not only to stimulate an innate immune response mediated by Toll-like receptors (TLRs), but also to deliver target protein directly to antigen presenting cells, eliciting an antigen-specific helper T cell (CD4) and killer T cells (CD8) cellular immune response to eliminate diseased cells.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
- Code names
- GI-5005
Resolves to
What you can answer from here — as of June 12, 2020
Which companies are running trials of GI-5005, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account